Lymphocyte monitoring as a predictor of renal allograft rejection
- PMID: 335987
- PMCID: PMC1396313
- DOI: 10.1097/00000658-197711000-00004
Lymphocyte monitoring as a predictor of renal allograft rejection
Abstract
The ability to predict acute renal allograft rejection episodes or infectious potentials by immunologic monitoring was studied in 15 renal transplant recipients. Specifically, total circulating erythrocyte- (E) and erythrocyte-antibody-complement (EAC) rosetting cells were serially studied for the first two months after transplantation and related to immunosuppressive therapy and rejection activity. Total circulating, E-rosetting cells (T cells) were noted to be significantly depressed if rabbit anti-human thymocyte globulin (RAHTG) was used in the immunosuppression protocol. The rate at which these T cells repopulated the circulation was measured by calculating their slope (delta total E-rosettes/delta time). Patients with acute rejection had an average slope of 3.2 +/- 0.68 compared to those without rejection, whose slope was 0.74 +/- 0.35 (p less than 0.01). The rapid repopulation of T cells occurred about 10 days before clinical parameters of rejection were evident. The incidence of infection was greater in those patients with total E-rosettes less than 200/mm3. Serial monitoring of total E-rosetting cells after transplantation provides a diagnostic tool for predicting ensuing rejections and can also be used to gain information concerning the susceptibility to infection.
Similar articles
-
Monitoring and modulation of recipient immune responsiveness to prevent kidney graft rejection in the early post-transplant period.Proc Eur Dial Transplant Assoc. 1977;14:336-41. Proc Eur Dial Transplant Assoc. 1977. PMID: 341135
-
Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.N Engl J Med. 1981 Aug 6;305(6):308-14. doi: 10.1056/NEJM198108063050603. N Engl J Med. 1981. PMID: 6454075
-
Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.N Engl J Med. 1990 Apr 26;322(17):1175-82. doi: 10.1056/NEJM199004263221702. N Engl J Med. 1990. PMID: 2157982 Clinical Trial.
-
Basiliximab: a review of its use as induction therapy in renal transplantation.Drugs. 2003;63(24):2803-35. doi: 10.2165/00003495-200363240-00009. Drugs. 2003. PMID: 14664658 Review.
-
Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.Expert Opin Biol Ther. 2012 Aug;12(8):1031-42. doi: 10.1517/14712598.2012.689278. Epub 2012 May 15. Expert Opin Biol Ther. 2012. PMID: 22583145 Review.
Cited by
-
Active T and EA-rosette-forming cells in human cadaver renal allograft recipients.Clin Exp Immunol. 1979 Feb;35(2):236-41. Clin Exp Immunol. 1979. PMID: 373936 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources